期刊
ONCOLOGY LETTERS
卷 12, 期 2, 页码 944-950出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/ol.2016.4744
关键词
endometrial cancer; immunohistochemistry; PD-1; PD-L1; PD-L2
类别
资金
- National Institutes of Health [R01CA174714, P20GM103518]
- Department of Defense [W81XWH-14-1-0050, W81XWH-14-1-0149, W81XWH-14-1-0458, W81XWH-15-1-0444]
- Tulane Cancer Center
- Louisiana Cancer Research Consortium Fund
- Tulane's Institute of Integrated Engineering for Health and Medicine
- Service Center for Experts and Scholars of Hebei Province, China
- National Natural Science Foundation of China [NSFC 81172236, NSFC 81372505]
- Key Science and Technology Program of Sichuan Province, China [2013SZ0005]
- China Scholarship Council [201406240145]
Endometrial cancer (EC) is the most frequent gynecological nildignancy and a major cause of morbidity and mortality for women worldwide. Programmed cell death protein 1 (PD-1.) and its ligands programmed death ligand 1 (PD-L1) and programmed death I igand 2 (PD-L2) have been well studied in lung cancer, melanoma and renal-cell cancer. However, few studies have been performed in EC. The purpose of the present study was to assess the expression of PD-1, PD-L1 and PD-L2 in 35 human normal endometrial tissue samples and 75 human EC tissue samples using immunohistochemical staining. It was found that 61.3% of ECs were positive for PD-i staining, which was almost exclusively found in the tumor-infiltrating immune cells. By contrast, PD-1 was not expressed in the tumor cells or normal endometrial tissues. It was also found that 14.3% of normal endometria and 17.3% of EC tissues were positive for PD-Ll expression, While 20.0% of normal endometrium and 37.3% of EC tissues were positive for PD-L2 expression; however, there was no statistically significant difference between the normal endometiium and EC tissues. PD-1 expression in the tumor-infiltrating immune cells was more frequently found in the moderately and poorly-differentiated ECs and non-endometrioid (type II) ECs than in the well-differentiated ECs and endometrioid (type I) ECs. Similarly, PD-L1 and PD-I,2 expression in the tumor-infiltrating immune cells was more frequently found in the moderately and poorly-differentiated ECs and type II ECs than in the type I ECs. The present findings indicate a possible better outcome for future treatment with anti-PD-1 or anti-PD-LI antibody-based therapies against these subgroups of endometrial cancers with frequent expression of the PDA/PD-LUPD-L2 axis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据